Get started
Author

Aram Bidikian

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
2024 · Benjamin Rolles, Jan Philipp Bewersdorf, et al. · Blood · 5
PDF
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database
2026 · Jan Philipp Bewersdorf, Tariq Kewan, et al. · Blood Cancer Journal · 3
PDF
Imetelstat in myeloid malignancies: current data and future directions
2025 · Aram Bidikian, Jan P. Bewersdorf, et al. · Expert Review of Anticancer Therapy · 2
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
2026 · Ghayas C. Issa, Branko Cuglievan, et al. · Journal of Clinical Oncology · 1
PDF
Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database
2025 · Jan Philipp Bewersdorf, Tariq Kewan, et al. · Blood · 1
PDF
Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis
2026 · Hira Mian, Muhammad Salman Faisal, et al. · Cancer
PDF
Reversal of systemic mastocytosis-induced liver cirrhosis with avapritinib treatment: case report
2026 · Aram Bidikian, Jan P. Bewersdorf, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
2026 · Doris K. Hansen, Danai Dima, et al. · Blood Cancer Journal
PDF
Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)
2026 · Benjamin Rolles, Jan Philipp Bewersdorf, et al. · American Journal of Hematology
PDF
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
2026 · Ghayas C. Issa, Branko Cuglievan, et al. · Journal of Clinical Oncology
PDF
JAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost‐Effectiveness Analysis
2026 · Barbara D. Lam, Satoko Ito, et al. · American Journal of Hematology
PDF
Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis
2025 · Aram Bidikian, Amer Al-Musa, et al. · Blood
PDF
Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database
2025 · Tariq Kewan, Jan Philipp Bewersdorf, et al. · Blood
PDF
The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome
2025 · Benjamin Rolles, Jan Philipp Bewersdorf, et al. · Blood
Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma
2025 · Cristian Taborda, Guannan Gong, et al. · Blood
PDF
Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule
2024 · Barbara D Lam, Satoko Ito, et al. · Blood
Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
2024 · Ted M. Getz, Tariq Kewan, et al. · Blood
PDF
Works count: 17
Citation count: 12
H-index: 2
I10-index:
Year
Topic
Type